|Application ||WB, IHC-P, IF, IP|
|Calculated MW||207721 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein G|
|Immunogen||Recombinant protein corresponing to the N-Terminal region of human BRCA1|
|Shelf Life||18 months from date of despatch.|
|Other Names||Breast cancer type 1 susceptibility protein, 6.3.2.-, RING finger protein 53, BRCA1, RNF53|
|Target/Specificity||Mouse anti-Human BRCA1 antibody, clone MS13 recognizes the human tumor supressor protein BRCA-1, also known as Breast cancer type 1 susceptibility protein or RING finger protein 53. BRCA1 is a 1863 amino acid, ~220kDa E3 ubiquitin-protein ligase playing a central role in DNA repair (Tibbettset al.2000), expressed in the nucleus during the S/G2 phase of the cell cycle (Durrant and Nickoloff 2005). Normal BRCA-1 acts as a tumor supressor protein and mutation or dysregulation of BRCA1 may indicate high risk of development of disease, including breast cancer (Budhram-Mahadeoet al.1999).Mouse anti-human BRCA-1, clone MS13 recognizes an epitope within the 304 amino acid N-Terminal (NT) region (Yoshikawaet al.1999) of human BRCA1.BRCA1 is expressed numerous organs including mammary and ovarian tissues (Mikiet al.1994) . Mutations in the BRCA-1 gene are associated with hereditary breast and ovarian cancers, particularly at a younger age of diagnosis. Women carrying BRCA1 mutations have a 50-95% chance of developing breast cancer in later life (Elit 2001), secondary cancers such as prostate or melanoma also frequently arise in the latter stages of both male and female breast cancer patients (Beneventoet al.2012), but genetic screening and increased awareness of preventative surgery, can reduce this risk significantly (Scheueret al.2002). However, in males pancreatic and prostate cancer appear to be more strongly associated with BRCA2 gene mutations (Gallagheret al.2010).BRCA1 is a key marker of triple-negative breast cancer (TNBC), a high risk aggressive cancer which makes up about 15% of invasive breast cancers, and lacks the benefit of specific targeted therapy (Duffyet al.2012). Triple-negative tumors are predominantly basal-like, poorly differentiated and of higher histological grade. Younger women have an increased rate of basal or BRCA related TNBC, compared with the higher proportion of apocrine, normal-like and rare subtypes of TNBC, seen in older women (Liuet al.2009). Studies looking at sporadic breast cancer, have shown that clone MS13 strongly correlates with poor patient prognosis, and appears to label the Δ11b splice variant of BRCA1, suggesting that Δ11b could act as a negative marker in the prognosis of sporadic breast cancer (Fraseret al.2003)Mouse anti-human BRCA1 antibody, clone MS13 is suitable for use in the immunohistochemical staining of human breast (Fraseret al.2003) and for immunofluorescence in multiple cell lines (Scullyet al.1996).|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human BRCA1 (N-Terminal) Antibody, clone MS13 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Scully, R. et al. (1996) Location of BRCA1 in human breast and ovarian cancer cells.Science 272: 123-125 2. Yoshikawa, K. et al. (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.Clin. Cancer Res. 5: 1249-1261 3. Ribeiro-Silva, A. et al. (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.Histopathology. 47: 458-66 4. Oliveira-Costa, J.P. et al. (2010) Significance of topoisomerase IIIß expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.Hum Pathol. 41: 1624-30. 1. Fraser, J.A. et al. (2003) A role for BRCA1 in sporadic breast cancer.Br J Cancer. 88: 1263-70.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.